Brokerages Set Carlsmed, Inc. (NASDAQ:CARL) PT at $21.33

Shares of Carlsmed, Inc. (NASDAQ:CARL) have been assigned an average recommendation of “Hold” from the five analysts that are currently covering the stock, Marketbeat reports. Two research analysts have rated the stock with a sell rating and three have given a buy rating to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $21.3333.

A number of equities research analysts have recently weighed in on CARL shares. Wall Street Zen upgraded Carlsmed from a “sell” rating to a “hold” rating in a research report on Saturday, February 14th. Weiss Ratings reiterated a “sell (e-)” rating on shares of Carlsmed in a report on Monday, December 22nd. The Goldman Sachs Group restated a “buy” rating and issued a $20.00 price objective on shares of Carlsmed in a report on Friday, January 9th. Zacks Research lowered shares of Carlsmed from a “hold” rating to a “strong sell” rating in a research note on Wednesday, February 25th. Finally, BTIG Research reiterated a “buy” rating and set a $24.00 price target on shares of Carlsmed in a research report on Monday, December 15th.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. BNP Paribas Financial Markets bought a new stake in shares of Carlsmed during the third quarter valued at approximately $33,000. JPMorgan Chase & Co. purchased a new position in Carlsmed during the third quarter valued at $37,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in Carlsmed during the third quarter valued at $42,000. Rhumbline Advisers bought a new stake in shares of Carlsmed during the 3rd quarter valued at $79,000. Finally, Wells Fargo & Company MN grew its position in shares of Carlsmed by 61.7% in the 4th quarter. Wells Fargo & Company MN now owns 7,834 shares of the company’s stock worth $97,000 after buying an additional 2,989 shares during the period.

Carlsmed Stock Performance

Shares of NASDAQ:CARL opened at $9.86 on Tuesday. The company has a current ratio of 8.87, a quick ratio of 8.74 and a debt-to-equity ratio of 0.16. The company has a 50-day moving average price of $12.06 and a 200-day moving average price of $12.97. The company has a market cap of $263.56 million and a price-to-earnings ratio of -2.69. Carlsmed has a 12 month low of $9.80 and a 12 month high of $17.19.

Carlsmed (NASDAQ:CARL) last posted its earnings results on Wednesday, February 25th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.11. The company had revenue of $15.16 million for the quarter, compared to analysts’ expectations of $15.20 million. Carlsmed had a negative return on equity of 72.60% and a negative net margin of 58.67%.

Carlsmed Company Profile

We are a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. We are focused on becoming the standard of care for spine fusion surgery. The aprevo Technology Platform consists of artificial intelligence (“AI”)-enabled software solutions, and interbody implants that we custom design for each patient’s unique pathology and vertebral bone topography, and single-use surgical instruments (the “aprevo Technology Platform”).